An Introduction to Dermatological Conditions
Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Dermatological Conditions Content
Su Lwin: Epidermolysis Bullosa and Gene Therapy (Part 2)
It was lovely to speak to our Expert Faculty member, Su Lwin (King’s College London, London, UK), about the development and clinical application of gene and cell therapy for individuals with epidermolysis bullosa. Questions Could you tell us a little about your research into spray-on gene therapy for recessive dystrophic epidermolysis bullosa? (0:18) Could you […]
Su Lwin: Epidermolysis Bullosa and Gene Therapy (Part 1)
It was lovely to speak to our Expert Faculty member, Su Lwin (King’s College London, London, UK), about the development and clinical application of gene and cell therapy for individuals with epidermolysis bullosa. Questions Could you give us a brief overview of epidermolysis bullosa (EB) and the unmet needs in its treatment? (0:20) What have […]
Rohit Aggarwal, ACR 2020 – Results of the ProDERM Study
We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented […]
A patient’s journey through the immuno-oncology treatment landscape in melanoma
Watch leading experts explore the impact of immunotherapy incorporating PD-1 blockade on the treatment landscape and patient experience in melanoma.
- Discuss factors to consider when selecting PD-1 inhibitors to treat melanoma
- Understand the rationale for combination regimens incorporating PD-1 blockade
- Analyse the role of long-term clinical and real-world data in informing treatment decisions
Martin Metz, EADV 2020 – Ligelizumab in Chronic Spontaneous Urticaria
It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab. His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria […]
Mehdi Rashighi, EADV 2020 – JAK inhibitors in Vitiligo
We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo. Questions What are the limitations of current therapeutic approaches for vitiligo? (0:26) What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56) […]
Giovanni Damiani, EADV 2020 – Highlights from the meeting
Dr Giovanni Damiani (University of Milan; Clinical Dermatology, IRCCS Instituto Ortopedico Galeazzi) gave us some of his key highlights from EADV 2020. Disclosures: Dr Giovanni Damiani has no disclosures to report. Support: Interview and filming supported by Touch Medical Media. Filmed as highlights of the 29th EADV Virtual Congress 2020.
Tiago Torres, EADV 2020 – The IL-23 Pathway in Psoriasis
We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors. Questions Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!